Share on StockTwits

Shares of Sinclair IS Pharma PLC (LON:SPH) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, AR Network reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is GBX 36.50 ($0.60).

Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Sinclair IS Pharma PLC from GBX 50 ($0.83) to GBX 45 ($0.74) in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Sinclair IS Pharma PLC from GBX 38 ($0.63) to GBX 44 ($0.73) in a research note on Tuesday, July 15th. They now have a “buy” rating on the stock. Finally, analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday, July 15th. They now have a GBX 40 ($0.66) price target on the stock.

Shares of Sinclair IS Pharma PLC (LON:SPH) opened at 28.96 on Monday. Sinclair IS Pharma PLC has a one year low of GBX 27.50 and a one year high of GBX 34.18. The stock’s 50-day moving average is GBX 29.91 and its 200-day moving average is GBX 30.52.

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.